Michael Baran, MBA, PH.D.
Michael Baran, MBA, PHD is Executive Director, WRD and Principal at Pfizer Ventures. Mike is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Accelerator NYC, AnTolRx, Biodesy, eFFECTOR, ImCheck, ImmunOs, and MISSION Therapeutics.
Prior to his current role, Mike held responsibilities in R&D portfolio strategy as well as managing scientific affairs for the R&D President’s office at Pfizer. Mike joined Pfizer from Nexomics Biosciences, a structural biology biotech company which he co-founded in 2006. Prior to his involvement at Nexomics he worked within the NIH Protein Structure Initiative’s Northeast Structural Genomics Consortium coordinating protein structure production efforts, including bioinformatics, protein expression/purification and 3D protein structure determination.
Mike received his BA in Biochemistry from Syracuse University, holds a MBA from Rutgers Business School, and a PhD in Biochemistry from Robert Wood Johnson Medical School / Rutgers, the State University of New Jersey.